Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The APLABE-PCI is a single-center, randomized, open-label, controlled, dose-escalating,
parallel-group study, which is designed to assess the anti-platelet effect of berberine in
approximately 64 patients receiving aspirin and clopidogrel who are at > 8 but ≤ 40 weeks
after percutaneous coronary intervention.